

Laura Mezquita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7629805/publications.pdf>

Version: 2024-02-01

112
papers

9,240
citations

159585

30
h-index

43889

91
g-index

114
all docs

114
docs citations

114
times ranked

12995
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
2	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. <i>Annals of Oncology</i> , 2019, 30, 1321-1328.	1.2	842
3	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	1.6	747
4	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	7.1	599
5	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	7.1	567
6	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018, 88, 38-47.	2.8	248
7	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1244-1254.	1.1	178
8	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017, 60, 60-68.	7.7	125
9	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	1.1	119
10	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	7.0	114
11	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1147-1157.	6.4	103
12	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6671-6682.	7.0	95
13	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
14	Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 102-102.	1.6	72
15	CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. <i>Cell Reports Medicine</i> , 2020, 1, 100127.	6.5	70
16	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	7.1	70
17	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 383-391.	1.1	58
18	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.	1.4	57

#	ARTICLE	IF	CITATIONS
19	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	2.8	53
20	Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. <i>European Journal of Cancer</i> , 2020, 129, 71-79.	2.8	45
21	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 301-322.	1.1	43
22	Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102906.	4.4	43
23	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	2.8	42
24	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9010-9010.	1.6	40
25	Durvalumab for the treatment of non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 627-639.	2.5	38
26	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.7	38
27	Radon and Lung Cancer: Current Trends and Future Perspectives. <i>Cancers</i> , 2022, 14, 3142.	3.7	37
28	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 116, 182-189.	2.8	36
29	Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 108, 88-96.	2.8	36
30	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	3.0	36
31	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020, 12, 2827.	3.7	35
32	Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e497-e510.	2.6	35
33	<i>EGFR</i> C797S, <i>EGFR</i> T790M and <i>EGFR</i> sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. <i>Oncotarget</i> , 2018, 9, 37393-37406.	1.8	34
34	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. <i>Frontiers in Immunology</i> , 2019, 10, 1505.	4.8	34
35	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988553.	2.6	32
36	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.	2.8	32

#	ARTICLE	IF	CITATIONS
37	Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	31
38	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. <i>Cancers</i> , 2020, 12, 2234.	3.7	31
39	Integrin- α V-mediated activation of TGF- β 2 regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. <i>Nature Communications</i> , 2021, 12, 5209.	12.8	30
40	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	1.1	29
41	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020, 12, 3625.	3.7	27
42	Safety of osimertinib in EGFR-mutated non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1239-1248.	2.4	25
43	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	3.0	25
44	Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer. <i>PLoS ONE</i> , 2018, 13, e0204490.	2.5	24
45	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 122, 340-347.	6.4	24
46	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	2.8	24
47	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1400-1407.	1.1	23
48	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	7.0	23
49	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. <i>Lung Cancer</i> , 2021, 159, 45-55.	2.0	23
50	Sumario ejecutivo de las recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. <i>Archivos De Bronconeumología</i> , 2016, 52, 378-388.	0.8	20
51	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2022, 103, 102335.	7.7	19
52	Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Npj Precision Oncology</i> , 2021, 5, 67.	5.4	17
53	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	5.4	16
54	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. <i>Journal of Clinical Oncology</i> , 2018, 36, 9003-9003.	1.6	16

#	ARTICLE	IF	CITATIONS
55	CD8 ⁺ PD-1 ⁺ to CD4 ⁺ PD-1 ⁺ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. , 2022, 10, e004012.		16
56	The role of brigatinib in crizotinib-resistant non-small cell lung cancer. Cancer Management and Research, 2018, Volume 10, 123-130.	1.9	14
57	The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research, 2020, 9, 967-970.	2.8	13
58	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE, 2020, 15, e0234302.	2.5	13
59	Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. Lung Cancer, 2022, 166, 255-264.	2.0	13
60	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
61	Durvalumab in non-small-cell lung cancer patients: current developments. Future Oncology, 2018, 14, 205-222.	2.4	12
62	Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2018, 13, e215-e217.	1.1	12
63	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. Lung Cancer, 2021, 155, 114-119.	2.0	12
64	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. JTO Clinical and Research Reports, 2020, 1, 100023.	1.1	11
65	Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9034-9034.	1.6	11
66	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 102.	5.4	11
67	Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. European Radiology, 2020, 30, 5021-5028.	4.5	10
68	The Role of Violent Video Game Exposure, Personality, and Deviant Peers in Aggressive Behaviors Among Adolescents: A Two-Wave Longitudinal Study. Cyberpsychology, Behavior, and Social Networking, 2021, 24, 32-40.	3.9	10
69	Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).. Journal of Clinical Oncology, 2019, 37, 9107-9107.	1.6	10
70	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 1149-1160.	2.0	9
71	Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. Case Reports in Oncological Medicine, 2021, 2021, 1-5.	0.3	8
72	Spontaneous tumor lysis syndrome in the setting of small cell lung cancer: Report of two cases and review of the literature. Cancer Treatment and Research Communications, 2016, 9, 92-95.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 305-312.e3.	2.6	7
74	Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e215-e216.	1.1	6
75	Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.. <i>Journal of Thoracic Disease</i> , 2016, 8, 2997-3002.	1.4	5
76	Letter to the Editor about Sorich et al.. <i>Journal of Thoracic Oncology</i> , 2019, 14, e209.	1.1	5
77	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	3.7	5
78	Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 735-735.	1.6	5
79	Acrometástasis como presentación inicial de un adenocarcinoma de pulmón en una mujer joven. <i>Archivos De Bronconeumología</i> , 2016, 52, 482-483.	0.8	4
80	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3758.	3.7	4
81	Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the ISEND model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3015.	1.6	4
82	Vaccine Therapy in Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2022, 10, 740.	4.4	4
83	Targeting molecular alterations in non-small-cell lung cancer: what's next?. <i>Personalized Medicine</i> , 0, , .	1.5	4
84	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2017, 112, 10-15.	2.0	3
85	Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient. <i>Annals of Thoracic Surgery</i> , 2020, 109, e397-e399.	1.3	3
86	Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e54-e56.	2.6	3
87	Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer. <i>Cancer Research</i> , 2021, 81, 448-448.	0.9	3
88	Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12038-12038.	1.6	3
89	Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15102-e15102.	1.6	3
90	Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , 2020, 38, 545-545.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Nivolumab-induced pneumonitis complicated by cyst formation. <i>Lung Cancer</i> , 2018, 122, 258-259.	2.0	2
92	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1230-1239.	2.0	2
93	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. <i>Respiratory Medicine and Research</i> , 2020, 78, 100788.	0.6	2
94	Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, 13, 1176. <i>Cancers</i> , 2021, 13, 3624.	3.7	2
95	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	2.4	2
96	Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations. <i>Future Oncology</i> , 2020, 16, 1665-1668.	2.4	1
97	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	2.6	1
98	Abstract 1867: Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches. , 2020, , .		1
99	An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9095-9095.	1.6	1
100	A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1782-1784.	1.1	1
101	Documento de consenso de la Sociedad Española de Cirugía Torácica (SECT). Seguimiento a largo plazo de los pacientes operados de cáncer de pulmón. <i>Cirugía Española (English Edition)</i> , 2022, , .	0.1	1
102	Síndrome neurológico progresivo inusual en adenocarcinoma de pulmón epidermal growth factor receptor mutado: carcinomatosis menáigea invasiva, un diagnóstico de autopsia. <i>Archivos De Bronconeumología</i> , 2016, 52, 571-572.	0.8	0
103	Congenital Bronchial Artery to Pulmonary Artery Fistula in a Patient With Lung Cancer Involving the Carina. <i>Annals of Thoracic Surgery</i> , 2016, 101, e89.	1.3	0
104	Pseudoprogresión en una paciente con adenocarcinoma pulmonar metastásico tratada con nivolumab. <i>Archivos De Bronconeumología</i> , 2019, 55, 168-169.	0.8	0
105	Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts). <i>Annals of Oncology</i> , 2019, 30, ii48.	1.2	0
106	Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2015-2015.	1.6	0
107	Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3055-3055.	1.6	0
108	Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9535-9535.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Central nervous system progression and liquid biopsy in patients with oncogene addicted non-small cell lung cancer treated with ALK/ROS1 inhibitors. Precision Cancer Medicine, 0, 3, 25-25.	1.8	0
110	Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer. , 2019, , .		0
111	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. Clinical Lung Cancer, 2022, , .	2.6	0
112	The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.. Journal of Clinical Oncology, 2022, 40, 2551-2551.	1.6	0